Provectus Biopharmaceuticals Announces Acceptance of PV-10 P

KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 (rose bengal sodium) as an immune vaccine adjuvant will be presented on a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2023 annual meeting to be held in San Diego, CA from November 1-5. This PV-10 research has been led by Aru Narendran, MD, PhD and his team of researchers at the Cumming School o

Related Keywords

Canada , Calgary , Alberta , San Diego , California , United States , Heather Raines , Exchange Commission , University Of Calgary , Cumming School Of Medicine , Society For Immunotherapy Of Cancer , National Institutes Of Health , Provectus Biopharmaceuticals Inc , Aru Narendran , Cumming School , World Health Organization , National Institutes , Provectus , Jobs , Provectus Biopharmaceuticals , Nc , Clinical Development Programs , Drug Discovery Programs , The Company , Vaccine Adjuvant ,